Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/163559
Title: Fasting plasma glucose is an independent predictor of survival in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy
Author: Bergamino Sirvén, Milana
Rullán, Antonio J.
Saigí, Maria
Peiró, Inmaculada
Montanya Mias, Eduard
Palmero, Ramón
Ruffinelli, José Carlos
Navarro Martin, Arturo
Arnaiz, María Dolores
Brao, Isabel
Aso, Samantha
Padrones, Susana
Cardenal, Felipe
Nadal, Ernest
Keywords: Diabetis
Càncer de pulmó
Glucosa
Diabetes
Lung cancer
Glucose
Issue Date: 21-Feb-2019
Publisher: BioMed Central
Abstract: Background: Diabetes is related with increased cancer mortality across multiple cancer types. Its role in lung cancer mortality is still unclear. We aim to determine the prognostic value of fasting plasma glucose (FPG) and diabetes mellitus in patients with locally advanced non-small cell lung cancer (NSCLC) treated with concurrent chemoradiotherapy. Methods: One-hundred seventy patients with stage III NSCLC received definitive concurrent chemoradiotherapy from 2010 to 2014. Clinico-pathological data and clinical outcome was retrospectively registered. Fifty-six patients (33%), met criteria for type 2 diabetes mellitus (T2DM) at baseline. The prognostic value of FPG and other clinical variables was assessed. Overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplan-Meier method and Cox proportional models and log-rank test were used. Results: With a median follow-up of 36 months, median PFS was 8.0 months and median OS was 15.0 months in patients with FPG ≥7 mmol/L compared to 20 months (HR 1.13; 95% CI 1.07-1.19, p < 0.001) and 31 months (HR 1.09; 95% CI 1.04-1.15; p < 0.001) respectively, for patients with FPG < 7 mmol/L. In the multivariate analysis of the entire cohort adjusted by platinum compound and comorbidities, high levels of FPG as a continuous variable (HR 1.14; 95% CI 1.07-1.21; p < 0.001), the presence of comorbidity (HR 1.72; 95% CI 1.12-2.63; p = 0.012), and treatment with carboplatin (HR 1.95; 95% CI 1.26-2.99; p = 0.002) were independent predictors for shorter OS. In additional multivariate models considering non-diabetic patients as a reference group, diabetic patients with poor metabolic control (HbA1c > 8.5%) (HR 4.53; 95% CI 2.21-9.30; p < 0.001) and those receiving insulin (HR 3.22; 95% CI 1.90-5.46 p < 0.001) had significantly independent worse OS. Conclusion: Baseline FPG level is an independent predictor of survival in our cohort of patients with locally advanced NSCLC treated with concurrent chemoradiotherapy. Studies in larger cohorts of patients are warranted to confirm this relevant association.
Note: Reproducció del document publicat a: https://doi.org/10.1186/s12885-019-5370-5
It is part of: BMC Cancer, 2019, vol. 19, p. 165
URI: http://hdl.handle.net/2445/163559
Related resource: https://doi.org/10.1186/s12885-019-5370-5
ISSN: 1471-2407
Appears in Collections:Articles publicats en revistes (Ciències Clíniques)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
687825.pdf1.15 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons